Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Med. lab ; 27(1): 51-64, 2023. ilus, Tabs
Article in Spanish | LILACS | ID: biblio-1414243

ABSTRACT

El virus de Epstein-Barr (VEB) fue el primer virus asociado a neoplasias en humanos. Infecta el 95 % de la población mundial, y aunque usualmente es asintomático, puede causar mononucleosis infecciosa y se relaciona con más de 200.000 casos de neoplasias al año. De igual forma, se asocia con esclerosis múltiple y otras enfermedades autoinmunes. A pesar de ser catalogado como un virus oncogénico, solo un pequeño porcentaje de los individuos infectados desarrollan neoplasias asociadas a VEB. Su persistencia involucra la capacidad de alternar entre una serie de programas de latencia, y de reactivarse cuando tiene la necesidad de colonizar nuevas células B de memoria, con el fin de sostener una infección de por vida y poder transmitirse a nuevos hospederos. En esta revisión se presentan las generalidades del VEB, además de su asociación con varios tipos de neoplasias, como son el carcinoma nasofaríngeo, el carcinoma gástrico, el linfoma de Hodgkin y el linfoma de Burkitt, y la esclerosis múltiple. Adicionalmente, se describen los mecanismos fisiopatológicos de las diferentes entidades, algunos de ellos no completamente dilucidados


Epstein-Barr virus (EBV) was the first virus associated with human cancer. It infects 95% of the world's population, and although it is usually asymptomatic, it causes infectious mononucleosis. It is related to more than 200,000 cases of cancer per year, and is also associated with multiple sclerosis and other autoimmune diseases. Despite being classified as an oncogenic virus, only a small percentage of infected individuals develop EBV-associated cancer. Its persistence involves the ability to alternate between a series of latency programs, and the ability to reactivate itself when it needs to colonize new memory B cells, in order to sustain a lifelong infection and be able to transmit to new hosts. In this review, the general characteristics of EBV are presented, in addition to its association with various types of cancers, such as nasopharyngeal carcinoma, gastric carcinoma, Hodgkin's lymphoma and Burkitt's lymphoma, and multiple sclerosis. Additionally, the pathophysiological mechanisms of the different entities are described, some of them not completely elucidated yet


Subject(s)
Humans , Herpesvirus 4, Human/physiology , Epstein-Barr Virus Infections/complications , Stomach Neoplasms/physiopathology , Stomach Neoplasms/virology , Hodgkin Disease/physiopathology , Hodgkin Disease/virology , Nasopharyngeal Neoplasms/physiopathology , Nasopharyngeal Neoplasms/virology , Burkitt Lymphoma/physiopathology , Burkitt Lymphoma/virology , Carcinogenesis , Nasopharyngeal Carcinoma/physiopathology , Nasopharyngeal Carcinoma/virology , Multiple Sclerosis/physiopathology , Multiple Sclerosis/virology
2.
J. oral res. (Impresa) ; 7(4): 141-144, abr. 27, 2018. ilus
Article in English | LILACS | ID: biblio-1120821

ABSTRACT

Burkitt's lymphoma, a form of non-hodgkin lymphoma, is a neoplastic monoclonal proliferation of lymphoid cells in areas of the immune system. it can occur in HIV-positive patients, as AIDS is related to the development of non- hodgkin lymphoma. burkitt's lymphoma is a rare subtype, highly prevalent in patients with AIDS. incisional biopsy, in situ hybridization and computerized axial tomography are the appropriate tests to determine the characterize of the lesions. the case of a 4-year-old HIV-positive patient, who developed burkitt's lymphoma of the oral cavity, is reported in this paper. the aim of this case report is to describe the course of the pathology, taking into account its clinical imaging characteristics and treatment.


Subject(s)
Humans , Male , Child, Preschool , Mandibular Neoplasms/pathology , Mandibular Neoplasms/drug therapy , HIV Infections/complications , Burkitt Lymphoma/pathology , Burkitt Lymphoma/drug therapy , Burkitt Lymphoma/virology , Mandibular Neoplasms/surgery , Burkitt Lymphoma/surgery
3.
Rev. chil. infectol ; 34(5): 507-510, oct. 2017. graf
Article in Spanish | LILACS | ID: biblio-899751

ABSTRACT

Resumen Las manifestaciones clínicas en los niños con infección por el virus de la inmunodeficiencia humana (VIH) de transmisión perinatal, pueden ser de inicio precoz o tardío. El linfoma asociado a VIH es una manifestación tardía que se asocia a estadios avanzados de inmunosupresión. Se presenta el caso de un escolar de 9 años con diagnóstico de novo de infección por VIH que debutó con un linfoma de Burkitt. En niños, la frecuencia de esta asociación es de 1-2% con pocos casos reportados en la literatura médica.


Children with perinatal human immunodeficiency virus (HIV) infection can present early or late clinical disease. HIV-associated lymphoma is a later manifestation that is associated with advanced immunosuppression (acquired immunodeficiency syndrome -AIDS). This is a case of a 9-year-old boy with recent diagnosis of HIV with Burkitt's lymphoma as first clinical manifestation. In children, the frequency of this association is very low and there are few cases reported.


Subject(s)
Humans , Male , Child , Burkitt Lymphoma/virology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/congenital , Lymphoma, AIDS-Related/virology , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Burkitt Lymphoma/diagnosis , Burkitt Lymphoma/drug therapy , Treatment Outcome , Lymphoma, AIDS-Related/diagnosis , Lymphoma, AIDS-Related/drug therapy , Infectious Disease Transmission, Vertical , Disease Progression , Antiretroviral Therapy, Highly Active
4.
Yonsei Medical Journal ; : 287-290, 2006.
Article in English | WPRIM | ID: wpr-51463

ABSTRACT

This brief communication focuses on aspects of a recent case report (Yonsei Med J 2005;46:425-30) on a full and sustained remission of Hodgkin's lymphoma (HL) after a single day of chemotherapy. A septic episode required stopping chemotherapy and starting amphotericin B and acyclovir. Remission evidence was seen within days of starting these. A review of research supporting the notion that amphotericin B can reactivate latent Epstein-Barr virus and thus allow acyclovir to kill infected HL cells is given. Experimental work is required to confirm or refute this possibility. If successful, amphotericin B and acyclovir treatment could be extended to other EBV-driven cancers such as Burkitt's lymphoma, nasopharyngeal carcinoma and the occasional EBV-related epithelial cancer of the breast, colon, prostate, and others.


Subject(s)
Humans , Virus Activation , Tumor Necrosis Factor-alpha/metabolism , Remission Induction , Hodgkin Disease/drug therapy , Herpesvirus 4, Human/metabolism , Ganciclovir/therapeutic use , Drug Synergism , Burkitt Lymphoma/virology , Anti-Bacterial Agents/pharmacology , Amphotericin B/pharmacology , Acyclovir/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL